{"id":306154,"date":"2026-10-14T09:14:06","date_gmt":"2026-10-14T03:44:06","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=306154"},"modified":"2026-10-14T09:14:06","modified_gmt":"2026-10-14T03:44:06","slug":"orchid-pharma-vs-beta-drugs-vs-gujarat-kidney","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/","title":{"rendered":"Orchid Pharma vs Beta Drugs vs Gujarat Kidney: Which Stock Should You Track"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Orchid Pharma PE 548.30, mkt cap Rs 5,877 crore. Beta Drugs PE 45.47, mkt cap Rs 2,104 crore. Gujarat Kidney and Super Speciality PE 85.50, mkt cap Rs 1,429 crore.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality is a side-by-side comparison of three companies from the pharma and healthcare space. On this comparison, Orchid Pharma carries a market capitalisation of about Rs 5,877 crore, against Rs 2,104 crore for Beta Drugs and Rs 1,429 crore for Gujarat Kidney and Super Speciality, with return on equity of 1.34%, 16.95% and 6.14% respectively. Each company&#8217;s numbers are presented here without a declared preference, since the right stock depends on an investor&#8217;s own criteria.<\/p>\n<\/div>\n<p>Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality starts with the core numbers most investors compare within the pharma and healthcare segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.<\/p>\n<p>All three names sit in the pharma and healthcare bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/#Orchid_Pharma_Beta_Drugs_and_Gujarat_Kidney_and_Super_Speciality_Company_Overview\" title=\"Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality: Company Overview\">Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality: Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/#Orchid_Pharma_vs_Beta_Drugs_vs_Gujarat_Kidney_and_Super_Speciality_Valuation_and_Profitability_Snapshot\" title=\"Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality: Valuation and Profitability Snapshot\">Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality: Valuation and Profitability Snapshot<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/#Orchid_Pharma_vs_Beta_Drugs_vs_Gujarat_Kidney_and_Super_Speciality_Latest_Quarterly_Results\" title=\"Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality: Latest Quarterly Results\">Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality: Latest Quarterly Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/#Orchid_Pharma_vs_Beta_Drugs_vs_Gujarat_Kidney_and_Super_Speciality_Five-Quarter_Revenue_and_Net_Profit_Trend\" title=\"Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality: Five-Quarter Revenue and Net Profit Trend\">Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality: Five-Quarter Revenue and Net Profit Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/#What_Should_Investors_Look_at_Beyond_These_Numbers\" title=\"What Should Investors Look at Beyond These Numbers?\">What Should Investors Look at Beyond These Numbers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/#FAQs_on_Orchid_Pharma_vs_Beta_Drugs_vs_Gujarat_Kidney_and_Super_Speciality\" title=\"FAQs on Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality\">FAQs on Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/#What_is_the_market_cap_difference_between_Orchid_Pharma_Beta_Drugs_and_Gujarat_Kidney_and_Super_Speciality\" title=\"What is the market cap difference between Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?\">What is the market cap difference between Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/#What_are_the_PE_and_PB_ratios_of_Orchid_Pharma_Beta_Drugs_and_Gujarat_Kidney_and_Super_Speciality\" title=\"What are the PE and PB ratios of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?\">What are the PE and PB ratios of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/#Which_of_the_three_has_the_highest_ROE\" title=\"Which of the three has the highest ROE?\">Which of the three has the highest ROE?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/#Which_of_these_three_stocks_pays_the_highest_dividend_yield\" title=\"Which of these three stocks pays the highest dividend yield?\">Which of these three stocks pays the highest dividend yield?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/#What_is_the_debt_to_equity_ratio_for_Orchid_Pharma_Beta_Drugs_and_Gujarat_Kidney_and_Super_Speciality\" title=\"What is the debt to equity ratio for Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?\">What is the debt to equity ratio for Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/#What_were_the_latest_quarterly_revenue_and_net_profit_of_Orchid_Pharma_Beta_Drugs_and_Gujarat_Kidney_and_Super_Speciality\" title=\"What were the latest quarterly revenue and net profit of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?\">What were the latest quarterly revenue and net profit of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney\/#Does_this_comparison_recommend_one_of_Orchid_Pharma_Beta_Drugs_and_Gujarat_Kidney_and_Super_Speciality\" title=\"Does this comparison recommend one of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?\">Does this comparison recommend one of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Orchid_Pharma_Beta_Drugs_and_Gujarat_Kidney_and_Super_Speciality_Company_Overview\"><\/span><strong>Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality: Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Orchid Pharma<\/strong> is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 5,877 crore, a return on equity of 1.34% and a book value of Rs 261.22 per share. Its quarterly revenue moved from Rs 274.76 crore in June 2025 to Rs 306.00 crore in June 2026, a change of +11.4%.<\/p>\n<p><strong>Beta Drugs<\/strong> is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,104 crore, a return on equity of 16.95% and a book value of Rs 221.65 per share. Its quarterly revenue moved from Rs 103.20 crore in June 2025 to Rs 127.13 crore in June 2026, a change of +23.2%.<\/p>\n<p><strong>Gujarat Kidney and Super Speciality<\/strong> is a listed Indian company in the pharma and healthcare space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 1,429 crore, a return on equity of 6.14% and a book value of Rs 32.03 per share. Its quarterly revenue moved from Rs 15.27 crore in June 2025 to Rs 34.98 crore in June 2026, a change of +129.1%.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Orchid_Pharma_vs_Beta_Drugs_vs_Gujarat_Kidney_and_Super_Speciality_Valuation_and_Profitability_Snapshot\"><\/span><strong>Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality: Valuation and Profitability Snapshot<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/orchpharma\/orchid-pharma-ltd-share-price-today\">Orchid Pharma<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/beta\/beta-drugs-ltd-share-price-today\">Beta Drugs<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/gksl\/gujarat-kidney-n-sup-sp-l-share-price-today\">Gujarat Kidney and Super Speciality<\/a><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Market Cap (approx.)<\/td>\n<td>Rs 5,877 crore<\/td>\n<td>Rs 2,104 crore<\/td>\n<td>Rs 1,429 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>548.30<\/td>\n<td>45.47<\/td>\n<td>85.50<\/td>\n<\/tr>\n<tr>\n<td>PB Ratio<\/td>\n<td>3.76<\/td>\n<td>8.56<\/td>\n<td>5.66<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity (ROE)<\/td>\n<td>1.34%<\/td>\n<td>16.95%<\/td>\n<td>6.14%<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM, Rs)<\/td>\n<td>1.79<\/td>\n<td>41.74<\/td>\n<td>2.12<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.00%<\/td>\n<td>0.00%<\/td>\n<td>0.00%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.28<\/td>\n<td>0.60<\/td>\n<td>0.12<\/td>\n<\/tr>\n<tr>\n<td>Book Value per Share (Rs)<\/td>\n<td>261.22<\/td>\n<td>221.65<\/td>\n<td>32.03<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data<\/strong><\/a><\/p>\n<p>On valuation, Orchid Pharma trades at a PE of 548.30 and a PB of 3.76, Beta Drugs at a PE of 45.47 and a PB of 8.56, while Gujarat Kidney and Super Speciality trades at a PE of 85.50 and a PB of 5.66. On return on equity, the three post 1.34%, 16.95% and 6.14% respectively, and on dividend yield they stand at 0.00%, 0.00% and 0.00%. Orchid Pharma has the highest market capitalisation of the three at Rs 5,877 crore, while Gujarat Kidney and Super Speciality has the lowest at Rs 1,429 crore. Orchid Pharma has the highest PE ratio of the three at 548.30, while Beta Drugs has the lowest at 45.47. Beta Drugs has the highest return on equity of the three at 16.95%, while Orchid Pharma has the lowest at 1.34%. Beta Drugs has the highest debt to equity ratio of the three at 0.60, while Gujarat Kidney and Super Speciality has the lowest at 0.12. Debt to equity is 0.28, 0.60 and 0.12 for the three respectively.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Orchid_Pharma_vs_Beta_Drugs_vs_Gujarat_Kidney_and_Super_Speciality_Latest_Quarterly_Results\"><\/span><strong>Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality: Latest Quarterly Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Company<\/th>\n<th>Latest Quarter Revenue<\/th>\n<th>Latest Quarter Net Profit<\/th>\n<th>YoY Change (Revenue)<\/th>\n<th>QoQ Change (Revenue)<\/th>\n<th>YoY Change (Net Profit)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Orchid Pharma<\/td>\n<td>Rs 306.00 crore<\/td>\n<td>Rs 2.58 crore<\/td>\n<td>+11.4%<\/td>\n<td>-18.6%<\/td>\n<td>NA<\/td>\n<\/tr>\n<tr>\n<td>Beta Drugs<\/td>\n<td>Rs 127.13 crore<\/td>\n<td>Rs 16.49 crore<\/td>\n<td>+23.2%<\/td>\n<td>+31.3%<\/td>\n<td>+40.9%<\/td>\n<\/tr>\n<tr>\n<td>Gujarat Kidney and Super Speciality<\/td>\n<td>Rs 34.98 crore<\/td>\n<td>Rs 5.32 crore<\/td>\n<td>+129.1%<\/td>\n<td>+11.8%<\/td>\n<td>-1.5%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Orchid_Pharma_vs_Beta_Drugs_vs_Gujarat_Kidney_and_Super_Speciality_Five-Quarter_Revenue_and_Net_Profit_Trend\"><\/span><strong>Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality: Five-Quarter Revenue and Net Profit Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality, which helps separate a one-quarter move from a steadier pattern.<\/p>\n<p><strong>Quarterly revenue (Rs crore)<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Orchid Pharma<\/th>\n<th>Beta Drugs<\/th>\n<th>Gujarat Kidney and Super Speciality<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>June 2025<\/td>\n<td>Rs 274.76 crore<\/td>\n<td>Rs 103.20 crore<\/td>\n<td>Rs 15.27 crore<\/td>\n<\/tr>\n<tr>\n<td>September 2025<\/td>\n<td>Rs 204.29 crore<\/td>\n<td>Rs 106.38 crore<\/td>\n<td>Rs 13.02 crore<\/td>\n<\/tr>\n<tr>\n<td>December 2025<\/td>\n<td>Rs 212.88 crore<\/td>\n<td>Rs 89.58 crore<\/td>\n<td>Rs 23.31 crore<\/td>\n<\/tr>\n<tr>\n<td>March 2026<\/td>\n<td>Rs 376.10 crore<\/td>\n<td>Rs 96.85 crore<\/td>\n<td>Rs 31.29 crore<\/td>\n<\/tr>\n<tr>\n<td>June 2026<\/td>\n<td>Rs 306.00 crore<\/td>\n<td>Rs 127.13 crore<\/td>\n<td>Rs 34.98 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Quarterly net profit (Rs crore)<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Orchid Pharma<\/th>\n<th>Beta Drugs<\/th>\n<th>Gujarat Kidney and Super Speciality<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>June 2025<\/td>\n<td>-Rs 6.89 crore<\/td>\n<td>Rs 11.70 crore<\/td>\n<td>Rs 5.40 crore<\/td>\n<\/tr>\n<tr>\n<td>September 2025<\/td>\n<td>-Rs 3.33 crore<\/td>\n<td>Rs 12.22 crore<\/td>\n<td>Rs 2.88 crore<\/td>\n<\/tr>\n<tr>\n<td>December 2025<\/td>\n<td>-Rs 12.15 crore<\/td>\n<td>Rs 8.52 crore<\/td>\n<td>Rs 3.71 crore<\/td>\n<\/tr>\n<tr>\n<td>March 2026<\/td>\n<td>Rs 24.84 crore<\/td>\n<td>Rs 9.05 crore<\/td>\n<td>Rs 4.83 crore<\/td>\n<\/tr>\n<tr>\n<td>June 2026<\/td>\n<td>Rs 2.58 crore<\/td>\n<td>Rs 16.49 crore<\/td>\n<td>Rs 5.32 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Orchid Pharma reported revenue of Rs 274.76 crore in June 2025 and Rs 306.00 crore in June 2026, a change of +11.4% across the period. Its highest quarterly revenue in this window was Rs 376.10 crore in March 2026. Net profit stood at Rs 2.58 crore in June 2026, which is a net profit margin of 0.84%. Orchid Pharma reported a net loss in June 2025, September 2025 and December 2025.<\/p>\n<p>Beta Drugs reported revenue of Rs 103.20 crore in June 2025 and Rs 127.13 crore in June 2026, a change of +23.2% across the period. Its highest quarterly revenue in this window was Rs 127.13 crore in June 2026. Net profit stood at Rs 16.49 crore in June 2026, which is a net profit margin of 12.97%.<\/p>\n<p>Gujarat Kidney and Super Speciality reported revenue of Rs 15.27 crore in June 2025 and Rs 34.98 crore in June 2026, a change of +129.1% across the period. Its highest quarterly revenue in this window was Rs 34.98 crore in June 2026. Net profit stood at Rs 5.32 crore in June 2026, which is a net profit margin of 15.21%.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality live prices.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Should_Investors_Look_at_Beyond_These_Numbers\"><\/span><strong>What Should Investors Look at Beyond These Numbers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Beyond the metrics above, investors comparing these three pharma and healthcare names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export orders, patient volumes and capacity utilisation. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.<\/p>\n<p>It also helps to read the latest quarterly filings and investor presentations of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality highlights how differently three companies in the same pharma and healthcare segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information as of October 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Orchid_Pharma_vs_Beta_Drugs_vs_Gujarat_Kidney_and_Super_Speciality\"><\/span><strong>FAQs on Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_cap_difference_between_Orchid_Pharma_Beta_Drugs_and_Gujarat_Kidney_and_Super_Speciality\"><\/span><strong>What is the market cap difference between Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of October 2026, Orchid Pharma has a market cap of approximately Rs 5,877 crore, Beta Drugs is at approximately Rs 2,104 crore, and Gujarat Kidney and Super Speciality is at approximately Rs 1,429 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_PE_and_PB_ratios_of_Orchid_Pharma_Beta_Drugs_and_Gujarat_Kidney_and_Super_Speciality\"><\/span><strong>What are the PE and PB ratios of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of October 2026, the PE ratios stand at 548.30, 45.47 and 85.50 respectively, and the price to book ratios stand at 3.76, 8.56 and 5.66 respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_the_three_has_the_highest_ROE\"><\/span><strong>Which of the three has the highest ROE?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality post ROE of 1.34%, 16.95% and 6.14% respectively as of October 2026. Beta Drugs has the highest return on equity of the three at 16.95%, while Orchid Pharma has the lowest at 1.34%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_of_these_three_stocks_pays_the_highest_dividend_yield\"><\/span><strong>Which of these three stocks pays the highest dividend yield?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality carry dividend yields of 0.00%, 0.00% and 0.00% respectively.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_debt_to_equity_ratio_for_Orchid_Pharma_Beta_Drugs_and_Gujarat_Kidney_and_Super_Speciality\"><\/span><strong>What is the debt to equity ratio for Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Orchid Pharma carries a debt to equity of 0.28, Beta Drugs of 0.60, and Gujarat Kidney and Super Speciality of 0.12.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_the_latest_quarterly_revenue_and_net_profit_of_Orchid_Pharma_Beta_Drugs_and_Gujarat_Kidney_and_Super_Speciality\"><\/span><strong>What were the latest quarterly revenue and net profit of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> For Q1 FY27 (quarter ended June 2026), Orchid Pharma reported revenue of Rs 306.00 crore and net profit of Rs 2.58 crore, Beta Drugs reported revenue of Rs 127.13 crore and net profit of Rs 16.49 crore, and Gujarat Kidney and Super Speciality reported revenue of Rs 34.98 crore and net profit of Rs 5.32 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Does_this_comparison_recommend_one_of_Orchid_Pharma_Beta_Drugs_and_Gujarat_Kidney_and_Super_Speciality\"><\/span><strong>Does this comparison recommend one of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor&#8217;s own criteria and research.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the market cap difference between Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of October 2026, Orchid Pharma has a market cap of approximately Rs 5,877 crore, Beta Drugs is at approximately Rs 2,104 crore, and Gujarat Kidney and Super Speciality is at approximately Rs 1,429 crore.\"}},{\"@type\":\"Question\",\"name\":\"What are the PE and PB ratios of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of October 2026, the PE ratios stand at 548.30, 45.47 and 85.50 respectively, and the price to book ratios stand at 3.76, 8.56 and 5.66 respectively.\"}},{\"@type\":\"Question\",\"name\":\"Which of the three has the highest ROE?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality post ROE of 1.34%, 16.95% and 6.14% respectively as of October 2026. Beta Drugs has the highest return on equity of the three at 16.95%, while Orchid Pharma has the lowest at 1.34%.\"}},{\"@type\":\"Question\",\"name\":\"Which of these three stocks pays the highest dividend yield?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality carry dividend yields of 0.00%, 0.00% and 0.00% respectively.\"}},{\"@type\":\"Question\",\"name\":\"What is the debt to equity ratio for Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Orchid Pharma carries a debt to equity of 0.28, Beta Drugs of 0.60, and Gujarat Kidney and Super Speciality of 0.12.\"}},{\"@type\":\"Question\",\"name\":\"What were the latest quarterly revenue and net profit of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"For Q1 FY27 (quarter ended June 2026), Orchid Pharma reported revenue of Rs 306.00 crore and net profit of Rs 2.58 crore, Beta Drugs reported revenue of Rs 127.13 crore and net profit of Rs 16.49 crore, and Gujarat Kidney and Super Speciality reported revenue of Rs 34.98 crore and net profit of Rs 5.32 crore.\"}},{\"@type\":\"Question\",\"name\":\"Does this comparison recommend one of Orchid Pharma, Beta Drugs and Gujarat Kidney and Super Speciality?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality compared on market cap, PE, PB, ROE, dividend yield and debt to equity, as of October 2026.<\/p>\n","protected":false},"author":35,"featured_media":306153,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[11016,1019],"class_list":["post-306154","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-pharma-and-healthcare","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["306153"],"rank_math_title":["Orchid Pharma vs Beta Drugs vs Gujarat Kidney"],"rank_math_description":["Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality compared on market cap, PE, PB, ROE, dividend yield and debt to equity, as of October 2026."],"rank_math_focus_keyword":["Orchid Pharma vs Beta Drugs vs Gujarat Kidney and Super Speciality"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/orchid-pharma-vs-beta-drugs-vs-gujarat-kidney-which-stock-should-you-track.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/306154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=306154"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/306154\/revisions"}],"predecessor-version":[{"id":306155,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/306154\/revisions\/306155"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/306153"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=306154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=306154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=306154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}